- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
HBA and Healthcare Companies Partner in Gender Parity Collaborative
The Healthcare Businesswomen’s Association (HBA) announced that 12 healthcare and life science companies have started a partnership to advance gender parity progress in the industry. The founding member companies serve as role models with all 12 organizations supporting internal women’s leadership networks and more than half recognized by national business media outlets for progressive diversity and inclusion programs, along with representing a work force of more than 750,000 employees collectively globally.
While similar corporate partnerships exist, the HBA’s Collaborative is different in that all member companies are in the healthcare and life science business. The twelve founding member companies are Advanced Clinical, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, GlaxoSmithKline, Medidata Solutions, Novartis, Pfizer, Quest Diagnostics, Genentech, a member of the Roche group, and Sanofi.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
